A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer

Soo Jin Park, Suk Joon Chang, Dong Hoon Suh, Tae Wook Kong, Heekyoung Song, Tae Hun Kim, Jae Weon Kim, Hee Seung Kim, Sung Jong Lee

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences